|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
multiple interactions
|
ISO
|
[arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of BIRC5 protein
|
CTD |
PMID:27794399 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155
|
|
G
|
Ccnd1
|
cyclin D1
|
multiple interactions
|
ISO
|
[PKI 166 co-treated with PD 173074] results in decreased expression of CCND1 protein
|
CTD |
PMID:15377668 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Fgf1
|
fibroblast growth factor 1
|
multiple interactions
|
ISO
|
PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein]
|
CTD |
PMID:15709206 |
|
NCBI chr18:30,937,670...31,023,786
Ensembl chr18:30,939,870...30,961,393
|
|
G
|
Fgfr1
|
Fibroblast growth factor receptor 1
|
decreases activity multiple interactions decreases expression
|
ISO
|
PD 173074 results in decreased activity of FGFR1 protein [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Arsenic Trioxide promotes the reaction [PD 173074 results in decreased expression of FGFR1 protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of FGFR1 protein]
|
CTD |
PMID:22683780 PMID:27794399 |
|
NCBI chr16:73,194,631...73,249,855
Ensembl chr16:73,194,631...73,249,855
|
|
G
|
Fgfr3
|
fibroblast growth factor receptor 3
|
decreases activity
|
ISO
|
PD 173074 results in decreased activity of FGFR3 protein
|
CTD |
PMID:15029211 |
|
NCBI chr14:81,211,800...81,227,215
Ensembl chr14:81,211,800...81,227,209
|
|
G
|
Fgfr4
|
fibroblast growth factor receptor 4
|
multiple interactions decreases activity
|
ISO
|
PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein] PD 173074 results in decreased activity of FGFR4 protein
|
CTD |
PMID:15377668 PMID:15709206 |
|
NCBI chr17:9,466,686...9,481,423
Ensembl chr17:9,466,692...9,481,389
|
|
G
|
Gdnf
|
glial cell derived neurotrophic factor
|
multiple interactions
|
EXP
|
PD 173074 inhibits the reaction [Docosahexaenoic Acids results in increased expression of GDNF mRNA]; PD 173074 inhibits the reaction [Docosahexaenoic Acids results in increased secretion of GDNF protein]
|
CTD |
PMID:28797567 |
|
NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:58,621,327...58,647,240
|
|
G
|
Hgf
|
hepatocyte growth factor
|
multiple interactions
|
ISO
|
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]
|
CTD |
PMID:22683780 |
|
NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
decreases phosphorylation multiple interactions decreases expression
|
ISO EXP
|
PD 173074 results in decreased phosphorylation of MAPK1 protein PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein] PD 173074 results in decreased expression of MAPK1 protein PD 173074 inhibits the reaction [Docosahexaenoic Acids results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:15029211 PMID:25953896 PMID:27794399 PMID:28797567 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
decreases phosphorylation multiple interactions decreases expression
|
ISO EXP
|
PD 173074 results in decreased phosphorylation of MAPK3 protein PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein] PD 173074 results in decreased expression of MAPK3 protein PD 173074 inhibits the reaction [Docosahexaenoic Acids results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:15029211 PMID:25953896 PMID:27794399 PMID:28797567 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Met
|
MET proto-oncogene, receptor tyrosine kinase
|
multiple interactions
|
ISO
|
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]
|
CTD |
PMID:22683780 |
|
NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions
|
ISO
|
[arsenic trioxide co-treated with PD 173074] results in increased expression of PARP1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in increased expression of PARP1 protein modified form; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in increased expression of PARP1 protein modified form
|
CTD |
PMID:27794399 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Phlpp1
|
PH domain and leucine rich repeat protein phosphatase 1
|
multiple interactions
|
ISO
|
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]; PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:25953896 |
|
NCBI chr13:22,823,132...23,045,619
Ensembl chr13:22,823,132...23,045,619
|
|
G
|
Raf1
|
Raf-1 proto-oncogene, serine/threonine kinase
|
decreases expression multiple interactions
|
ISO
|
PD 173074 results in decreased expression of RAF1 protein; PD 173074 results in decreased expression of RAF1 protein modified form [arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein; [arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein modified form; arsenic trioxide promotes the reaction [PD 173074 results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein]
|
CTD |
PMID:27794399 |
|
NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:150,352,160...150,412,813
|
|
G
|
Rps6kb1
|
ribosomal protein S6 kinase B1
|
multiple interactions
|
ISO
|
[PKI 166 co-treated with PD 173074] results in decreased activity of RPS6KB1 protein
|
CTD |
PMID:15377668 |
|
NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238
|
|
G
|
Src
|
SRC proto-oncogene, non-receptor tyrosine kinase
|
multiple interactions decreases expression
|
ISO
|
[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein; [Arsenic Trioxide results in increased susceptibility to PD 173074] which results in decreased expression of SRC protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in decreased expression of SRC protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein modified form]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein] PD 173074 results in decreased expression of SRC protein; PD 173074 results in decreased expression of SRC protein modified form
|
CTD |
PMID:27794399 |
|
NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462
|
|
G
|
Tbx3
|
T-box transcription factor 3
|
multiple interactions
|
ISO
|
PD 173074 inhibits the reaction [afimoxifene results in increased expression of TBX3 protein]; PD 173074 inhibits the reaction [Estrogens results in increased expression of TBX3 protein]
|
CTD |
PMID:21098263 |
|
NCBI chr12:42,540,378...42,555,490
Ensembl chr12:42,540,378...42,554,171
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
multiple interactions
|
ISO
|
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA]]; PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA]
|
CTD |
PMID:26800359 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|